FDA advisory panel backs limits on painkiller scripts
|Endo Pharmaceuticals petitioned the FDA to require tamper-resistant generics--courtesy of Endo Pharmaceuticals|
The FDA's path through the swamp of painkiller abuse advanced a bit on Friday. An advisory panel backed new controls on hydrocodone drugs, including cough medications and pain pills. The committee recommended prescription limits, in a 19-10 vote, in an effort to tighten up access.
The FDA doesn't always follow the advice of its outside experts, but it usually does. The split vote opens up the question a bit, however. As The New York Times reports, some of the panelists were skeptical that new limits would forestall abuse of the drugs. The same limits already apply to oxycodone products--including the notoriously abused OxyContin.
Plus, the agency recently decided that non-tamper-resistant copies of OxyContin and similar drugs could be sold, even though the branded versions are no longer on the market in their old, easily abused formulations. Endo Pharmaceuticals ($ENDP), which makes an oxycodone drug, Opana, had petitioned the FDA to require the generics to be tamper-resistant, as its new Opana product is. The agency decided that patient access to pain relief was more important. (Endo then sued FDA, but a judge declined to force the agency's hand.)
But that's not to say that FDA isn't keen on preventing abuse. The agency is convening a two-day meeting next month to consider prescribing guidelines for opioid drugs. And earlier this month, the FDA issued guidance for makers of tamper-resistant pills.
- read the NYT piece
Panel vote will add to FDA pain drug puzzle
Judge blocks Endo's effort to block generic pain meds
White House adds voice to debate over generic painkillers
Should FDA usher old-style opioid generics onto the market?
FDA to look again at reclassifying hydrocodone combos